What is Isabl?
Established in 2020, Isabl is at the forefront of precision oncology, offering a comprehensive test that integrates whole genome and transcriptome data to inform cancer care. The company's innovative approach aims to provide deeper insights for oncologists and patients, facilitating more personalized and effective treatment strategies. This focus on advanced genomic analysis positions Isabl as a key player in the rapidly evolving field of cancer diagnostics and personalized medicine.
How much funding has Isabl raised?
Isabl has raised a total of $3M across 1 funding round:
Angel/Seed
$3M
Angel/Seed (2022): $3M with participation from Y Combinator, BoxOne Ventures, and Two Sigma Ventures
Key Investors in Isabl
Y Combinator
Y Combinator is a renowned accelerator program that provides seed funding and mentorship to early-stage startups, helping them to grow and secure further investment.
BoxOne Ventures
BoxOne Ventures is an investment firm that operates within the financial services sector, likely focusing on companies with strong growth potential.
Two Sigma Ventures
Two Sigma Ventures is an early-stage venture capital firm that invests in transformative companies leveraging information growth and computing power, with a focus on technology that enhances human potential.
What's next for Isabl?
With this major enterprise-level funding, Isabl is poised for significant expansion. The capital infusion is expected to accelerate product development, enhance its genomic sequencing capabilities, and broaden its market reach. Strategic investments of this magnitude typically signal a company's readiness to scale operations, invest in research and development, and potentially explore new therapeutic areas or partnerships. Isabl's next phase will likely involve solidifying its position as a leader in precision oncology by leveraging its advanced technology to improve patient outcomes.
See full Isabl company page
